mellitus (T2DM) have NAFLD ( Rinella 2015 , Bril & Cusi 2016 , Cusi 2016 ), and as many as ~30–50% may develop the more severe form of the disease known as nonalcoholic steatohepatitis (NASH), characterized by hepatocyte necrosis (ballooning) and lobular
Search Results
Srilaxmi Kalavalapalli, Fernando Bril, Joy Guingab, Ariana Vergara, Timothy J Garrett, Nishanth E Sunny, and Kenneth Cusi
Jie Wei, Xia Sun, Yajie Chen, Yuanyuan Li, Liqiong Song, Zhao Zhou, Bing Xu, Yi Lin, and Shunqing Xu
population in Western countries and 9–40% of people in Asian countries ( Farrell & Larter 2006 ). A subset of patients with NAFLD may progress to nonalcoholic steatohepatitis (NASH), a more severe form of hepatic damage associated with inflammation, fibrosis
Makoto Ito, Akira Gomori, Jun Suzuki, Shigeharu Tsujioka, Minoru Sasaki, Masao Matsuda, Maria A Bednarek, Masahiko Ito, Akane Ishihara, Hisashi Iwaasa, Douglas J MacNeil, and Akio Kanatani
, Caldwell & Crespo 2004 , Machado et al . 2006 ). Among NAFLD, nonalcoholic steatohepatitis (NASH) is characterized by fat accumulation with various degrees of inflammation, fibrosis, and necrosis ( Neuschwander-Tetri & Caldwell 2003 , Caldwell et al
Leke Wiering and Frank Tacke
(NAFL) can progress to non-alcoholic steatohepatitis (NASH) characterized by persistent inflammatory processes, which in turn can progress to NASH fibrosis. The long-term risk is the transition to liver cirrhosis. NAFLD is very often associated with
Raquel Barbuio, Marciane Milanski, Manoel B Bertolo, Mário J Saad, and Lício A Velloso
Introduction Non-alcoholic fatty liver disease (NAFLD) comprehends a large spectrum of clinicopathological conditions of the liver, ranging from steatosis to cirrhosis, and including steatohepatitis (NASH) and fibrosis ( Browning
Alex M DePaoli
( ClinicalTrials.gov March 4, 2014). Overall, these data provide promise for combination therapy for general obesity or at least a subset of obese patients. Leptin for nonalcoholic steatohepatitis NAFLD and nonalcoholic steatohepatitis (NASH) are a spectrum of
Jing Zhou, Honggui Li, Yuli Cai, Linqiang Ma, Destiny Matthews, Bangchao Lu, Bilian Zhu, Yanming Chen, Xiaoxian Qian, Xiaoqiu Xiao, Qifu Li, Shaodong Guo, Yuqing Huo, Liang Zhao, Yanan Tian, Qingsheng Li, and Chaodong Wu
and inflammatory mediators from extrahepatic tissues, simple steatosis progresses to non-alcoholic steatohepatitis (NASH) as the advanced form of NAFLD ( Cohen et al. 2011 , Chalasani et al. 2018 ). Epidemiological data indicate that NASH affects
Hong Xu, Yang Zhou, Yongxia Liu, Jian Ping, Qiyang Shou, Fangming Chen, and Ru Ruo
glycogenolysis and gluconeogenesis ( Radziuk & Pye 2001 ). Nonalcoholic fatty liver disease (NAFLD) is a spectrum of diseases ranging from simple steatosis to nonalcoholic steatohepatitis (NASH), which may progress to cirrhosis. NAFLD is strongly associated with
Yuriko Sakai, Hideyuki Arie, Yinhua Ni, Fen Zhuge, Liang Xu, Guanliang Chen, Naoto Nagata, Takuya Suzuki, Shuichi Kaneko, Tsuguhito Ota, and Mayumi Nagashimada
Introduction Nonalcoholic fatty liver disease (NAFLD) is one of the most common liver disorders and is often associated with obesity, diabetes, dyslipidemia, and insulin resistance. Nonalcoholic steatohepatitis (NASH) is a severe form of NAFLD
Cintia B Ueta, Gustavo W Fernandes, Luciane P Capelo, Tatiane L Fonseca, Flávia D'Angelo Maculan, Cecilia H A Gouveia, Patrícia C Brum, Marcelo A Christoffolete, Marcelo S Aoki, Carmen L Lancellotti, Brian Kim, Antonio C Bianco, and Miriam O Ribeiro
with WT mice ( Table 1 ). Also, high-fat feeding caused a much more dramatic increase in liver fat deposition in β 1 KO when compared with WT animals, leading to the development of nonalcoholic steatohepatitis ( Fig. 4 ). Table 1 Lack of β 1 adrenergic
